Cellumed Co (049180.KQ) Stock Price

Cellumed Co Price

CLOSED
1,009.00
​
Market closed

Over the last 19 years Cellumed Co grew revenue by 13.1% annually, reaching 140.19 B KRW. Earnings per share have grown at 54.9% per year over the last 9 years. For Cellumed Co, the net margin of -1.6% is down versus 8.2% a few years ago.

Cellumed Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellumed Co business model & stock analysis

Cellumed Co Ltd manufactures and distributes medical devices and biomaterials, including allografts for tissue repair, bone sponges, bone powders, and demineralized bone matrixes (DBMs) for bone regeneration. The company also produces biosimilars like bone morphogenetic protein 2 (BMP2) reagents and medical devices such as spinal fixation systems, joint replacements, and navigation systems. Cellumed sells these products domestically in Seoul and internationally to overseas markets. Cellumed’s primary customers are healthcare providers and medical institutions that require tissue repair solutions, bone regeneration products, and advanced medical devices. The company’s product portfolio targets orthopedic and spinal care segments, with a focus on biomaterials and surgical tools. Its biosimilars, including BMP2 reagents, cater to specialized medical applications requiring bone growth stimulation. The company generates revenue through direct sales of its medical devices and biomaterials to hospitals, clinics, and international distributors. Cellumed’s domestic market in Seoul serves local healthcare facilities, while its overseas sales expand its reach to global medical markets. The firm’s product range supports both routine and complex surgical procedures in orthopedics and spinal care.

Frequently asked questions about Cellumed Co

Converted at the current exchange rate, the Cellumed Co share trades at 0.69 EUR (1,009.00 KRW).

The revenue cannot currently be calculated for Cellumed Co.

The profit cannot currently be calculated for Cellumed Co.

The P/E ratio cannot be calculated for Cellumed Co at the moment.

The P/S cannot be calculated for Cellumed Co currently.

The Eulerpool Quality Score for Cellumed Co is 5/10.

The ISIN of Cellumed Co is KR7049180003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cellumed Co is 049180.KQ. The ticker symbol is used to trade Cellumed Co shares on the stock exchange.

Fair ValueTerminal
908.10 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
May 23, 2002
ISIN
KR7049180003
Cusip
Y3001M107
Market capitalization
49.10 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
28.94
P/B Ratio
5.86
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-26.68 %
Last updated Nov 18, 2026, 2:28 PM

Cellumed Co Peer Group

Cellumed Co FIGI

049180:KS · BBG000MR2N11049180:KQ · BBG000MR2PH9

All fundamentals and in-depth analysis of Cellumed Co

Our stock analysis for Cellumed Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cellumed Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.